People · Operator
Named in public records as an officer, director or promoter · active 2025–2025 · Biotechnology
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| DMC Biotechnologies, Inc. | — | Biotechnology | Series B | $48.1M | $5.4M | 2025 |
Josh Yelen at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Josh Yelen on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Doug Cameron | 1 | 5 |
| Alastair Cooper | 1 | 3 |
| Josko Bobanovic | 1 | 2 |
| Jim Flatt | 1 | 2 |
| K'LYNNE JOHNSON | 1 | 2 |
| Josko D. Bobanovic | 1 | 2 |
| Rob Van Der Meij | 1 | 2 |
| Matthew L. Lipscomb | 1 | 1 |
| Matthew Lipscomb | 1 | 1 |
| Doug D. Cameron | 1 | 1 |
| Alastair D. Cooper | 1 | 1 |
| Rob D. Van Der Meij | 1 | 1 |
| Carolyn D. Fritz | 1 | 1 |
| Michael D. Lynch | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.